SCHEMBL343830

SCHEMBL343830

CC(C)(NC(=O)c1ccccc1)C(=O)O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.65
CYP2C9 P11712 2/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
EPHX1 P07099 1/20 0.53
HDAC3 O15379 1/20 0.50
CA12 O43570 1/20 0.50
CA1 P00915 1/20 0.50
IDO1 P14902 1/20 0.50
ALOX15 P16050 1/20 0.50
HDAC1 Q13547 1/20 0.50
CA9 Q16790 1/20 0.50
HDAC7 Q8WUI4 1/20 0.50
HDAC2 Q92769 1/20 0.50
HSD17B10 Q99714 1/20 0.50
HDAC8 Q9BY41 1/20 0.50
HDAC6 Q9UBN7 1/20 0.50
NCOR2 Q9Y618 1/20 0.50
KDM4E B2RXH2 1/20 0.50
GAA P10253 1/20 0.47
PRSS1 P07477 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12024336 0.86 POLB (0.62) POLBCYP2C9SMN1; SMN2EPHX1HDAC3
SCHEMBL24534686 0.84 HDAC1 (0.60) POLBSMN1; SMN2HDAC3HDAC1HDAC8
SCHEMBL12302098 0.84 ALDH1A1 (0.55) POLBSMN1; SMN2HDAC1HDAC6GAA
SCHEMBL408310 0.83 CYP2C9 (0.67) POLBCYP2C9SMN1; SMN2EPHX1HDAC3
SCHEMBL16776702 0.82 OGG1 (0.50) POLBSMN1; SMN2HDAC3CA12HDAC1
SCHEMBL3755534 0.82 POLB (0.56) POLBSMN1; SMN2ALOX15KDM4ENPC1
SCHEMBL22987120 0.82 MAPT (0.49) POLBCYP2C9SMN1; SMN2HDAC1KDM4E
SCHEMBL1742088 0.82 EGLN1 (0.50) POLBKDM4EGAANPC1RAB9A
SCHEMBL9828913 0.82 SMN1; SMN2 (0.60) POLBSMN1; SMN2HDAC8HDAC6NPC1
SCHEMBL10504078 0.82 POLB (0.58) POLBCYP2C9SMN1; SMN2EPHX1HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140080788-A1 NOVEL BICYCLIC NITROGEN CONTAINING HETEROARYL TGR5 RECEPTOR MODULATORS BRISTOL-MYERS SQUIBB COMPANY 2014-03-20 US claimed
EP-2673260-A1 GLUCAGON RECEPTOR MODULATOR Pfizer Inc (US) 2013-12-18 EP claimed
WO-2012107850-A1 GLUCAGON RECEPTOR MODULATOR PFIZER INC. (US) 2012-08-16 WO claimed
US-4213784-A Process for producing heat developable light-sensitive compositions and elements FUJI PHOTO FILM CO., LTD. (JP) 1980-07-22 US claimed
CN-117777121-A Compounds and uses thereof 詹森药业有限公司 2024-03-29 CN disclosed
US-11873298-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-01-16 US disclosed
US-11873298-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-01-16 US disclosed
CN-116925066-A Indole thiazole ketone compound and application thereof 张所明 2023-10-24 CN disclosed
CN-110099898-B Compounds and uses thereof 优曼尼蒂治疗公司 2023-07-25 CN disclosed
CN-111196772-B Aroylamino isobutyryl derivative and application thereof 沈阳化工研究院有限公司 2022-09-30 CN disclosed
US-20200262828-A1 COMPOUNDS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2020-08-20 US disclosed
CN-111196772-A Aroylamino isobutyryl derivative and application thereof 沈阳化工研究院有限公司 2020-05-26 CN disclosed
WO-2009127722-A1 NOVEL MICROBIOCIDES SYNGENTA PARTICIPATIONS AG (CH) 2009-10-22 WO disclosed
CN-1356977-A Glucagon antagonists/inverse agonists NOVO NORDISK AS (DK) 2002-07-03 CN disclosed
EP-0226304-B1 COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC SANKYO COMPANY LIMITED (JP) 1991-08-28 EP disclosed
US-4757066-A Reduces renal toxicity SANKYO COMPANY LIMITED (JP) 1988-07-12 US disclosed
EP-0226304-A1 Composition containing a penem or carbapenem antibiotic SANKYO COMPANY LIMITED (JP) 1987-06-24 EP disclosed
EP-0014437-B1 NOVEL 1-ARYL-2-ACYLAMIDO-3-FLUORO-1-PROPANOLS, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SCHERING CORPORATION (US) 1983-02-23 EP disclosed
US-4213784-A Process for producing heat developable light-sensitive compositions and elements FUJI PHOTO FILM CO., LTD. (JP) 1980-07-22 US disclosed
EP-0001864-A1 Novel 6-oxygenated-3,20-dioxo-pregnane derivatives, process for the preparation thereof, and pharmaceutical compositions containing them Technobiotic Ltd. (CH) 1979-05-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11873298-B2 Compounds and uses thereof NLN, ACHE, CLN6 POLB 3788/4885CYP2C9 1658/4885SMN1; SMN2 13/4885
US-20140080788-A1 NOVEL BICYCLIC NITROGEN CONTAINING HETEROARYL TGR5 RECEPTOR MODULATORS GRK5, GPBAR1, GPR55 POLB 3238/4885CYP2C9 1392/4885SMN1; SMN2 3874/4885
US-20200262828-A1 COMPOUNDS AND USES THEREOF NLN, ACHE, CLN6 POLB 3788/4885CYP2C9 1658/4885SMN1; SMN2 13/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.